1. Home
  2. ASA vs WVE Comparison

ASA vs WVE Comparison

Compare ASA & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASA

ASA Gold and Precious Metals Limited

HOLD

Current Price

$63.93

Market Cap

914.2M

Sector

Industrials

ML Signal

HOLD

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$4.89

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASA
WVE
Founded
1958
2012
Country
United States
Singapore
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
914.2M
1.0B
IPO Year
2003
2015

Fundamental Metrics

Financial Performance
Metric
ASA
WVE
Price
$63.93
$4.89
Analyst Decision
Strong Buy
Analyst Count
0
16
Target Price
N/A
$29.81
AVG Volume (30 Days)
42.0K
3.2M
Earning Date
06-01-2026
04-28-2026
Dividend Yield
0.10%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,704,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$85.67
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
149.43
52 Week Low
$38.10
$5.01
52 Week High
$83.20
$21.73

Technical Indicators

Market Signals
Indicator
ASA
WVE
Relative Strength Index (RSI) 65.55 36.74
Support Level $61.86 N/A
Resistance Level $64.43 $6.33
Average True Range (ATR) 2.25 0.24
MACD 0.35 -0.02
Stochastic Oscillator 63.94 7.97

Price Performance

Historical Comparison
ASA
WVE

About ASA ASA Gold and Precious Metals Limited

ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Share on Social Networks: